Landos Biopharma, Inc.

41 articles with Landos Biopharma, Inc.

• Landos Biopharma’s Phase 2 Data of Omilancor in Ulcerative Colitis Accepted for Oral Presentation at the United European Gastroenterology Week 2021

  7/22/2021

  Landos Biopharma, Inc. announced that data from the Phase 2 clinical trial of omilancor in ulcerative colitis has been accepted for oral presentation at the upcoming United European Gastroenterology Week 2021.

• Landos Biopharma to Present at the Raymond James Virtual Human Health Innovation Conference

  6/14/2021

  Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE Advanced A.I. platform to discover and develop novel oral therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Raymond James Virtual Human Health Innovation Conference

• Landos Biopharma Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA for Omilancor in Mild-to-Moderate Active Ulcerative Colitis (UC) Patients

  6/14/2021

  Landos Biopharma, Inc. announced the successful outcome of an End-of-Phase 2 meeting with the U.S. Food and Drug Administration for omilancor, its lead candidate in late-stage clinical development for the treatment of mild-to-moderate active ulcerative colitis patients.

• Landos Biopharma to Present at the Jefferies Virtual Healthcare Conference - May 25, 2021

  5/25/2021

  Landos Biopharma, Inc. announced that Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos, will present at the upcoming Jefferies Virtual Healthcare Conference on Tuesday, June 1, 2021 at 11:00 AM EDT.

• Landos Biopharma Announces the Appointment of Tim M. Mayleben to its Board of Directors

  5/19/2021

  Landos Biopharma, Inc (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the appointment of Tim M. Mayleben to its Board of Directors.

• 

  LianBio Partners With Landos to Commercialize Colitis, Crohn’s Drugs in China

  5/17/2021

  Landos Biopharma partnered with Shanghai, China-based LianBio to develop and commercialize omilancor and NX-13 in Greater China and select Asian markets.

• Landos Biopharma Reports First Quarter 2021 Financial Results and Provides Business Updates

  5/17/2021

  Landos Biopharma, Inc, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced financial results for the first quarter ended March 31, 2021 and provided business updates.

• Landos Biopharma and LianBio Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Omilancor and NX-13 in Greater China and Select Asian Markets

  5/17/2021

  Landos Biopharma, Inc and LianBio announced an exclusive collaboration and license agreement for the development and commercialization of omilancor and NX-13 in Greater China and select Asian markets.

• Landos Biopharma Announces First Patient Dosed in a Phase 2 Study of Omilancor for Moderate-to-Severe Crohn’s Disease

  5/6/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that the Company has dosed the first patient in a Phase 2 study of omilancor, Landos’ novel, orally administered, gut-restricted LANCL2 agonist, for the treatment of moderate-to-severe Crohn’s disease.

• Landos Biopharma Announces First Patient Dosed in a Phase 1b Study of NX-13 for Ulcerative Colitis

  4/29/2021

  Landos’ second first-in-class product candidate designed to provide a safer and more convenient treatment for ulcerative colitis patients Topline results are expected in the first quarter of 2022

• Landos Biopharma to Present Two Late-Breaking Presentations on Therapeutic Potential of Omilancor and PX-69 at the 2021 American Association of Immunologists (AAI) Annual Meeting

  4/26/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that two late-breaking abstracts on preclinical data of omilancor in psoriasis and proof-of concept preclinical data of PX-69 in rheumatoid arthritis will be presented at the upcoming American Association of Immunologists Annual Meeting 2021.

• Landos Biopharma Announces the Appointment of Tiago Girão to its Board of Directors

  4/13/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced the appointment of Tiago Girão to its Board of Directors.

• Landos Biopharma Announces FDA Clearance of IND Application for Omilancor for the Treatment of Eosinophilic Esophagitis

  4/6/2021

  Landos Biopharma (NASDAQ: LABP), a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for omilancor (BT-11),

• Landos Biopharma to Participate in the SVB Leerink 10th Annual Global Healthcare Conference

  2/23/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, announced that Dr. Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer, will participate in a fireside chat at the upcoming virtual SVB Leerink 10th Annual Global Healthcare Conference on Wednesday, February 24, 2021 at 12:00 PM EST.

• 

  Money on the Move: February 3-9

  2/10/2021

  The cash just keeps coming for biopharma companies. Here’s a rundown of some of this week’s investment dollar recipients.
• 

  Life Sciences Companies Ringing the Nasdaq Bell this Week

  2/4/2021

  Sana Biotechnology led the way with a very large initial public offering that could bring the company’s market value to $4.6 billion or more. But it’s not the only IPO this week. Here’s a look.

• Landos Biopharma Announces Pricing of Initial Public Offering

  2/4/2021

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at the public offering price of $16.00 per share, for total gross proceeds of $100 million

• 

  Will Murky Trial Data Undercut Landos' $100 Million IPO Launch?

  1/14/2021

  On January 4, the company announced slightly murky data from its first-in-patients 12-week Phase II proof-of-concept trial of BT-11 for mild to moderate ulcerative colitis.

• Landos Biopharma Announces First Human Dosing in a Phase 1 Study of NX-13, its Novel Candidate for Inflammatory Bowel DiseaseNX-13 is the Company’s second first-in-class candidate to begin clinical development

  7/14/2020

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune disease, announced that the first patient has been dosed in a Phase 1 study of NX-13, the Company’s novel, orally administered therapeutic candidate for the treatment of inflammatory bowel disease.

• Landos Biopharma to Present at Two Upcoming Investor Conferences

  5/12/2020

  Landos Biopharma, a clinical-stage biopharmaceutical company focused on the discovery and development of therapeutics for patients with autoimmune diseases, today announced that Josep Bassaganya-Riera, Ph.D., Chairman, President and Chief Executive Officer of Landos, will present at the following upcoming investor conferences. Presentation Details: Event: UBS Virtual Global Healthcare Conference  Date:  Tuesday, May 19, 2020 Time: 1: